Similar results have been shown for the CUDC-907-mediated inhibition of cancer cell growth by inhibiting MYC levels in pancreatic adenocarcinoma, acute myeloid leukemia, and prostate cancer [20,21,35]. Here, MYC is linked to prostate cancer.